| ||Suven Participating at 4th CNS Partnering & Deal Making Conference in USA | 9/22/2011 10:20:09 AM|| |
| ||Suven Life Sciences Ltd has informed BSE regarding a Press Release dated September 22, 2011 titled "Suven Participating at 4th CNS Partnering & Deal Making Conference in USA"|
"Suven Life Sciences is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class therapies through the use of GPCR targets in CNS disorders for unmet medical needs covering potentially over $30 billion market , today announced that it is participating at 4 ONS Partnering & Deal making Conference held at San Francisco from 22nd to 23rd Sep 2011.
CNS Partnering & Deal. Making Conference is a CNS Diseases partnering a business development conference that gives global. biotechnology and pharmaceutical. companies an. opportunity to network with high-level executives from top pharma and various biotech/pharmaceutical companies, as well as explore potential collaborations, and learn about relevant CNS Disease issues and partnerships that will affect the industry. This event also provides a unique venue for attendees to learn about CNS Diseases business development trends, the CNS disease market, and novel technologies that shape up the industry.
Mr. Venkat Jasti CEO of Suven is scheduled to discuss the Company's corporate overview, business strategy and partnering activity by presenting their Phase 2 ready clinical candidate SUVN-502 for cognition in Alzheimer's and Schizophrenia and other pipeline compounds at this Partnering & Deal making conference where the world’s top notch investment professionals will present along with the most innovative companies who are decision makers.
Suven Life Sciences is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class therapies through the use of GPCR targets. The Company has twelve (12) internally-discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as ADHD, Dementia, Depression, Huntington’s disease, Parkinson’s disease and obesity in addition to developmental candidate SUVN-502 for Alzheimer’s disease and Schizophrenia."